Fig. 1

MYCN RNAi strongly upregulated DHA and ELOVL2 in neuroblastoma cell lines. a Heatmap representation of FA profiling indicates significantly (P < 0.05) up- (red) or downregulated (green) FAs in BE(2)-C cells treated for 72 h with the lentivirus expressing 2 MYCN shRNA or the negative control. b IMR32 and BE(2)-C cells were treated as described in (a). The change in DHA concentration was validated using ELISA. c DHA concentration of MYCN-amplified cell lines (IMR32 and BE(2)-C) and MYCN single-copy cell lines SK-N-AS were measured by ELISA. d The DHA concentration of SK-N-AS cells stably expressing the GFP control or MYCN was measured by ELISA. e and f IMR32 and BE(2)-C stably expressing negative control or MYCN shRNA. The change in DHA transport and synesis-related mRNA expression was measured by qRT-PCR (fold-change over negative control ± SD). g RNA expression pattern of ELOVL2 with MYCN amplified verse MYCN nonamplified in a cohort of 476 neuroblastoma. h MYCN and ELOVL2 mRNA expression of MYCN-amplified cell lines (IMR32 and BE(2)-C) and MYCN single-copy cell lines (SK-N-AS) were measured by qRT-PCR (fold-change over SK-N-AS ± SD). i MYCN and ELOVL2 mRNA expression of SK-N-AS cells stably expressing GFP control or MYCN were measured by qRT-PCR (fold-change over GFP control ± SD). j Using an MYCN and ELOVL2 antibody with the ß-actin loading control. MYCN RNAi efficiency and the change in ELOVL2 expression was validated by Western blots (left). The difference of MYCN and ELOVL2 between MYCN-amplified cell lines (IMR32 and BE(2)-C) and MYCN single-copy cell lines (SK-N-AS) was validated by Western blots (middle). MYCN overexpression efficiency and the change in ELOVL2 expression were validated by Western blots (right). *P < 0.05; **P < 0.01